Piper Sandler Puts its Weight Behind 2 ‘Strong Buy’ Cancer Stocks

Cancer remains 1 of the world’s deadliest challenges. Second lone to bosom disease, it claims 1 successful each six lives globally – astir 10 cardinal deaths each twelvemonth – and the numbers are inactive climbing arsenic manner factors specified arsenic smoking, mediocre diet, and inactivity proceed to instrumentality their toll.

• Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

For the biopharmaceutical industry, that grim world has translated into an tremendous opportunity. According to Precedence Research, the planetary marketplace for crab therapies was valued astatine $86.2 cardinal successful 2024 and roseate to $92.5 cardinal past year. Looking ahead, it is projected to astir treble to $175.2 cardinal by 2034, fueled by breakthroughs successful caller attraction approaches and a increasing propulsion toward personalized medicine.

Against this backdrop, Piper Sandler’s 5-star expert Kelsey Goodwin has picked 2 cancer-focused biopharma stocks she believes are particularly good positioned to payment from these trends.

Using the TipRanks platform, we took a person look astatine her picks – and however they stack up against the broader Wall Street consensus. Let’s dive in.

Olema Pharmaceuticals (OLMA)

Kicking disconnected Piper Sandler’s database is Olema, a clinical-stage biopharmaceutical institution focused squarely connected women’s cancers. The company’s efforts halfway connected a single, perchance best-in-class bosom crab therapy, palazestrant, which anchors its full R&D pipeline.

Olema’s pipeline presently has 7 tracks based connected palazestrant. The probe tracks scope from Phase 1 to Phase 3, and are investigating palazestrant arsenic a monotherapy and arsenic a combo therapy with assorted different crab drugs. Several of the objective studies are being conducted successful conjunction with larger spouse companies, Novartis and Pfizer.

Palazestrant, besides called pala, is simply a caller compound, designed to beryllium orally dosed. The cause is an ER (estrogen receptor) antagonist, and blocks crab compartment maturation and proliferation signals that are ER-mediated. The cause is nether probe arsenic a attraction for ER+/HER2- metastatic bosom cancer.

We should enactment that OLMA banal jumped sharply successful November of past year. That leap successful worth occurred aft Roche, a rival company, announced affirmative objective proceedings results from its ain candidate, giredestrant. This is simply a caller cause successful the aforesaid people arsenic pala, and its occurrence is considered a affirmative indicator for the aboriginal occurrence of palazestrant.